Interpace Diagnostics Group Inc. ( (IDXG) ) has released its Q2 earnings. Here is a breakdown of the information Interpace Diagnostics Group Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Interpace Biosciences, Inc. is a company specializing in molecular diagnostics, bioinformatics, and pathology services, primarily focused on cancer risk evaluation using advanced technology in personalized medicine. In its latest earnings report for the quarter ended June 30, 2025, Interpace Biosciences reported a decline in revenue compared to the previous year, with net revenue at $9.2 million, down from $12.0 million. Despite this, the company managed to achieve a gross profit of $5.3 million, although it faced a net loss of $640,000 for the quarter. Key financial metrics highlighted in the report include a decrease in cash and cash equivalents to $502,000 from $1.5 million at the end of 2024, and a reduction in total liabilities from $17.0 million to $13.5 million. The company also implemented a restructuring plan due to the loss of Medicare coverage for its PancraGEN test, which led to workforce reductions and cost-saving measures. Looking ahead, Interpace Biosciences plans to address its capital needs through improved margins, cost containment, and exploring additional funding options. The management remains focused on navigating the challenges posed by recent changes in reimbursement coverage and aims to sustain operations through strategic adjustments.